GGrantIndex
← Leaderboards

Scott D Cramer

Wake Forest University Health Sciences

Google Scholar ↗PubMed ↗ORCID ↗
$13,143,499
Attributed
$16,744,812
Total exposure
14
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.4M · FY2005–25
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$16,744,812 · 14

By mechanism

R01$8,003,004 · 5
U01$3,364,869 · 1
T32$3,098,193 · 1
R21$2,075,746 · 6
R29$203,000 · 1

Top collaborators

Most similar at Wake Forest University Health Sciences

Same institution · by research overlap

Others in their field

Top investigators on “Prostate”

Research focus

ProstateCellsMalignant Neoplasm Of ProstateIn VivoPathway InteractionsIn VitroGrowthTumorStem CellsMap3k7 GeneGenesPhenotypeTissuesSignal TransductionGene ExpressionTissue RecombinationMouse ModelProteinsCancer CellMutationLeadAnimal ModelSamplingPrimary Neoplasm

Grant awards (55)

Androgen Signaling in CaP with loss of MAP3K7 and CHD1$391,942
R01 · FY2025 · CA · contact PI
Training Program in Cancer Biology$333,455
T32 · FY2025 · CA
Androgen Signaling in CaP with loss of MAP3K7 and CHD1$372,346
R01 · FY2024 · CA · contact PI
Training Program in Cancer Biology$369,111
T32 · FY2024 · CA
Systems analysis of aggressive prostate cancer pathology$598,524
U01 · FY2023 · CA
Training Program in Cancer Biology$394,379
T32 · FY2023 · CA
Androgen Signaling in CaP with loss of MAP3K7 and CHD1$384,104
R01 · FY2023 · CA · contact PI
Systems analysis of aggressive prostate cancer pathology$794,056
U01 · FY2022 · CA
Androgen Signaling in CaP with loss of MAP3K7 and CHD1$384,104
R01 · FY2022 · CA · contact PI
Training Program in Cancer Biology$251,806
T32 · FY2022 · CA
Systems analysis of aggressive prostate cancer pathology$610,738
U01 · FY2021 · CA
Androgen Signaling in CaP with loss of MAP3K7 and CHD1$391,942
R01 · FY2021 · CA · contact PI
Systems analysis of aggressive prostate cancer pathology$745,463
U01 · FY2020 · CA
Training Program in Cancer Biology$421,320
T32 · FY2020 · CA
Systems analysis of aggressive prostate cancer pathology$616,088
U01 · FY2019 · CA
Training Program in Cancer Biology$362,640
T32 · FY2019 · CA
CHD1 and MAP3K7 coordinate deletion in aggressive ERG translocation negative prostate cancer$323,088
R01 · FY2019 · CA · contact PI
Training Program in Cancer Biology$356,567
T32 · FY2018 · CA
CHD1 and MAP3K7 coordinate deletion in aggressive ERG translocation negative prostate cancer$333,082
R01 · FY2018 · CA · contact PI
Training Program in Cancer Biology$376,004
T32 · FY2017 · CA
CHD1 and MAP3K7 coordinate deletion in aggressive ERG translocation negative prostate cancer$341,879
R01 · FY2017 · CA · contact PI
Autophagy regulation of prostate tumor development$169,106
R21 · FY2017 · CA
Training Program in Cancer Biology$5,412
T32 · FY2017 · CA
CHD1 and MAP3K7 coordinate deletion in aggressive ERG translocation negative prostate cancer$388,676
R01 · FY2016 · CA · contact PI
Training Program in Cancer Biology$227,499
T32 · FY2016 · CA
Autophagy regulation of prostate tumor development$202,928
R21 · FY2016 · CA
CHD1 and TAK1 Synthetic Lethality in Prostate Cancer$202,928
R21 · FY2016 · CA · contact PI
CHD1 and MAP3K7 coordinate deletion in aggressive ERG translocation negative prostate cancer$402,456
R01 · FY2015 · CA · contact PI
CHD1 and TAK1 Synthetic Lethality in Prostate Cancer$168,970
R21 · FY2015 · CA · contact PI
The prostate stem cell is a target of vitamin D chemoprevention$293,726
R01 · FY2014 · CA · contact PI
The prostate stem cell is a target of vitamin D chemoprevention$284,642
R01 · FY2013 · CA · contact PI
Tak1, a novel prostate cancer tumor suppressor$281,438
R01 · FY2013 · CA · contact PI
Isolation of Tumor Initiating Cells (TICs) using Contactless Dielectrophoresis$187,279
R21 · FY2013 · CA
Tak1, a novel prostate cancer tumor suppressor$307,069
R01 · FY2012 · CA · contact PI
The prostate stem cell is a target of vitamin D chemoprevention$302,810
R01 · FY2012 · CA · contact PI
Isolation of Tumor Initiating Cells (TICs) using Contactless Dielectrophoresis$180,252
R21 · FY2012 · CA
The prostate stem cell is a target of vitamin D chemoprevention$302,810
R01 · FY2011 · CA · contact PI
Tak1, a novel prostate cancer tumor suppressor$212,374
R01 · FY2011 · CA · contact PI
Tak1, a novel prostate cancer tumor suppressor$93,088
R01 · FY2011 · CA · contact PI
Tak1, a novel prostate cancer tumor suppressor$307,100
R01 · FY2010 · CA · contact PI
The prostate stem cell is a target of vitamin D chemoprevention$307,100
R01 · FY2010 · CA · contact PI
Tak1, a novel prostate cancer tumor suppressor$307,100
R01 · FY2009 · CA · contact PI
Vitamin D and Soy Isoflavone Inhibition of Prostate$251,038
R01 · FY2008 · CA · contact PI
Vitamin D and Soy Isoflavone Inhibition of Prostate$251,038
R01 · FY2007 · CA · contact PI
Vitamin D and Soy Isoflavone Inhibition of Prostate$258,536
R01 · FY2006 · CA · contact PI
Mitochondrial GRHPR and Hyperoxaluria$210,192
R21 · FY2006 · DK · contact PI
Vitamin D and Soy Isoflavone Inhibition of Prostate$264,758
R01 · FY2005 · CA
Mitochondrial GRHPR and Hyperoxaluria$179,375
R21 · FY2005 · DK
Prostate Specific Antigen and Prostate Ca. Progression$138,339
R21 · FY2005 · CA
Vitamin D and Soy Isoflavone Inhibition of Prostate$264,758
R01 · FY2004 · CA
Prostate Specific Antigen and Prostate Ca. Progression$148,127
R21 · FY2004 · CA
GPHRP KNOCKOUT MOUSE AS A MODEL OF HYPEROXALURIA$144,000
R21 · FY2003 · DK
GPHRP KNOCKOUT MOUSE AS A MODEL OF HYPEROXALURIA$144,250
R21 · FY2002 · DK
PTHRP AND PROSTATE GROWTH$101,500
R29 · FY2001 · DK
PTHRP AND PROSTATE GROWTH$101,500
R29 · FY2000 · DK